ライフサイエンスコーパス: atrial natriuretic peptide

1 ic* and pulmonary* vascular resistances, and atrial natriuretic peptide*.

2 tion of the cardiac-derived peptide hormone, atrial natriuretic peptide.

3 lar results were obtained for N-terminal pro-atrial natriuretic peptide.

4 sue weight assessment and gene expression of atrial natriuretic peptide.

5 ibute to the breakdown of bradykinin and the atrial natriuretic peptide.

6 mall peptides such as insulin, glucagon, and atrial natriuretic peptide.

7 Mz-ChA-1 responded only to atrial natriuretic peptide.

8 ypoxia can induce synthesis and secretion of atrial natriuretic peptide.

9 aritide is a 25-amino-acid synthetic form of atrial natriuretic peptide.

10 ing in the presence of chronically increased atrial natriuretic peptide.

11 -type natriuretic peptide in comparison with atrial natriuretic peptide.

12 e of chronically increased concentrations of atrial natriuretic peptide.

13 All patients showed low serum levels of atrial natriuretic peptide.

14 re healthy and demonstrated normal levels of atrial natriuretic peptide.

15 r function, and severely decreased levels of atrial natriuretic peptide.

16 cant even after adjusting for N-terminal pro-atrial natriuretic peptide.

17 ous frameshift mutation in the gene encoding atrial natriuretic peptide.

18 c protease responsible for the activation of atrial natriuretic peptide.

19 described stable fragment of N-terminal pro-atrial natriuretic peptide.

20 eptide was significantly more effective than atrial natriuretic peptide (16-fold increase in cyclic G

21 ose of SDZ-WAG 994, significant increases in atrial natriuretic peptide (216 +/- 137 to 407 +/- 146 p

22 intact internal mammary artery, 1 microM of atrial natriuretic peptide (26-fold increase in cyclic G

23 in -26%; aldosterone -32%; vasopressin -30%; atrial natriuretic peptide -27%).

24 C resulted in marked increases of myocardial atrial natriuretic peptide 4-hydroxy-2-nonenal (a marker

25 r greater, P=0.001), had increased levels of atrial natriuretic peptide (7.3 versus 4.9 pmol/L, P=0.0

26 t converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regul

27 Atrial natriuretic peptide, a hormone synthesized by the

28 mRNA from LV myocytes showed upregulation of atrial natriuretic peptide, a molecular marker of hypert

29 ms of natriuretic peptide receptors but that atrial natriuretic peptide acts primarily on the artery

30 n plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP exc

31 lier than the reduction of plasma volume and atrial natriuretic peptide after HeartMate implantation,

32 measured plasma volume and plasma levels of atrial natriuretic peptide, aldosterone, renin, and argi

33 , B-type natriuretic peptide, N-terminal pro-atrial natriuretic peptide, aldosterone, renin, fibrinog

34 ohumoral factors, cytokines, endothelin, and atrial natriuretic peptide all may participate in HPA ax

35 n-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could

36 ) of cardiac-specific genes (Nkx2.5, GATA-4, atrial natriuretic peptide, alpha- and beta-myosin heavy

37 Atrial natriuretic peptide also prevented stimulation of

38 Brain natriuretic peptide and atrial natriuretic peptide also released norepinephrine

39 leation, molecular up-regulation of released atrial natriuretic peptide, altered expression of classi

40 ion of the fetal gene program (ie, increased atrial natriuretic peptide and alpha skeletal actin gene

41 n human ventricles (n=13), message levels of atrial natriuretic peptide and AT(1) receptor were inver

42 for age and clinical covariates, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

43 In men, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

44 rdiovascular regulator that is stimulated by atrial natriuretic peptide and B-type natriuretic peptid

45 Atrial natriuretic peptide and B-type natriuretic peptid

46 ions of natriuretic peptides (N-terminal pro-atrial natriuretic peptide and B-type natriuretic peptid

47 s less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptid

48 eased expression of cardiac embryonic genes (atrial natriuretic peptide and beta-myosin heavy chain)

49 logical properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide

50 NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide

51 In competition binding experiments, atrial natriuretic peptide and brain type natriuretic pe

52 thod to quantitate mRNA expression levels of atrial natriuretic peptide and c-fos in an in vitro mode

53 The binding of atrial natriuretic peptide and C-type natriuretic peptid

54 Other substrates of IDE such as atrial natriuretic peptide and glucagon also competitive

55 llows a stepwise pattern, with resistance to atrial natriuretic peptide and marked sympathetic activa

56 s opposite effects, as do excess circulating atrial natriuretic peptide and overactivity of various i

57 ated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress mark

58 he expression of known hypertrophic markers (atrial natriuretic peptide) and transcription factor act

59 etic peptides (C-type natriuretic peptide >> atrial natriuretic peptide) and, to a much smaller exten

60 nosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine.

61 n, we found that norepinephrine, endothelin, atrial natriuretic peptide, and bradykinin had no signif

62 ion, LVEF, serum ACE, plasma angiotensin II, atrial natriuretic peptide, and brain natriuretic peptid

63 protein synthesis, cellular protein, prepro-atrial natriuretic peptide, and c-fos mRNAs and decrease

64 m salt (DEA/NO) or the natriuretic peptides, atrial natriuretic peptide, and C-type natriuretic pepti

65 itivities of their cGMP responses to DEA/NO, atrial natriuretic peptide, and C-type natriuretic pepti

66 rations for histology, middle neurofilament, atrial natriuretic peptide, and connexin (Cx) 43 reveale

67 agents at this time appear to be adenosine, atrial natriuretic peptide, and cyclosporine, with other

68 tches, the response of BKCa to nitric oxide, atrial natriuretic peptide, and dibutyryl cGMP (Bt2cGMP)

69 only marginally elevated by the addition of atrial natriuretic peptide, and in broken-cell preparati

70 ulate whereas somatostatin, cholecystokinin, atrial natriuretic peptide, and nitric oxide inhibit aci

71 ene-related peptide, adrenomedullin, amylin, atrial natriuretic peptide, and pituitary adenylate cycl

72 or norepinephrine, epinephrine, aldosterone, atrial natriuretic peptide, and plasma renin activity we

73 mic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (concentration r

74 for reduced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lip

75 lective PDE2 inhibitor BAY 60-7550 augmented atrial natriuretic peptide- and treprostinil-evoked pulm

76 Atrial natriuretic peptide (ANP) acts acutely to reduce

77 e-A (GC-A) receptor is known to require both atrial natriuretic peptide (ANP) and an adenine nucleoti

78 used to map the antagonistic effects between atrial natriuretic peptide (ANP) and angiotensin II (Ang

79 the EGR1-regulated cardioprotective peptides atrial natriuretic peptide (ANP) and B-type natriuretic

80 Cardiomyocytes secrete atrial natriuretic peptide (ANP) and B-type natriuretic

81 The cardiac natriuretic peptides (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic

82 of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain nat

83 Atrial natriuretic peptide (ANP) and brain natriuretic p

84 ctivation of a fetal gene program, including atrial natriuretic peptide (ANP) and brain natriuretic p

85 at baseline, messenger ribonucleic acid for atrial natriuretic peptide (ANP) and brain natriuretic p

86 , the expression of iNOS mRNA was induced by atrial natriuretic peptide (ANP) and C-type natriuretic

87 Physiological actions of atrial natriuretic peptide (ANP) and C-type natriuretic

88 Both atrial natriuretic peptide (ANP) and C-type natriuretic

89 The effect of atrial natriuretic peptide (ANP) and cyclic nucleotides

90 ct (IMCD) cells contributes to resistance to atrial natriuretic peptide (ANP) and the excessive sodiu

91 ntrations of plasma norepinephrine (PNE) and atrial natriuretic peptide (ANP) and the renin activity

92 Subnanomolar concentrations of atrial natriuretic peptide (ANP) and type C natriuretic

93 he natriuretic signaling pathway in RPE with atrial natriuretic peptide (ANP) and with membrane-perme

94 pertensive rat, implicated the gene encoding atrial natriuretic peptide (ANP) as a possible candidate

95 Atrial natriuretic peptide (ANP) binding sites have been

96 After atrial natriuretic peptide (ANP) binding to NPRA, ligand

97 o mediate its desensitization in response to atrial natriuretic peptide (ANP) binding.

98 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

99 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

100 Atrial natriuretic peptide (ANP) binds to natriuretic pe

101 GMP, 1-methyl-3-isobutylxanthine (IBMX), and atrial natriuretic peptide (ANP) but not 8-Br-cAMP mimic

102 ed the hypothesis that nitric oxide (NO) and atrial natriuretic peptide (ANP) can attenuate the effec

103 Atrial natriuretic peptide (ANP) can inhibit the release

104 ion (VE) natriuresis and renal resistance to atrial natriuretic peptide (ANP) characterize states of

105 Corin is a recently discovered pro-atrial natriuretic peptide (ANP) convertase that is abun

106 cardiac serine protease that acts as the pro-atrial natriuretic peptide (ANP) convertase.

107 Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effe

108 Atrial natriuretic peptide (ANP) depresses contractility

109 ibited hypertrophy concurrent with increased atrial natriuretic peptide (ANP) expression that depende

110 mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% incre

111 Activation of the atrial natriuretic peptide (ANP) gene is regarded as one

112 with Src, modulated basal and ET-stimulated atrial natriuretic peptide (ANP) gene promoter activity,

113 tudy was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronar

114 ciated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene.

115 mulated contractility, whereas 10 micromol/L atrial natriuretic peptide (ANP) had no effect.

116 Atrial natriuretic peptide (ANP) has a central role in r

117 The atrial natriuretic peptide (ANP) hormone is secreted by

118 The role of atrial natriuretic peptide (ANP) in regulating fetal car

119 osure to 3-morpholino-sydnonimine (SIN-1) or atrial natriuretic peptide (ANP) in the absence or in th

120 e main receptor that mediates the effects of atrial natriuretic peptide (ANP) in the regulation of pl

121 assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide (ANP) induced synthesis of in

122 Atrial natriuretic peptide (ANP) influences glucose home

123 Atrial natriuretic peptide (ANP) inhibited VPF signaling

124 Atrial natriuretic peptide (ANP) inhibits and aldosteron

125 Atrial natriuretic peptide (ANP) inhibits the proliferat

126 The cardiac hormone atrial natriuretic peptide (ANP) is a 28-amino acid (AA)

127 Atrial natriuretic peptide (ANP) is a cardiac hormone es

128 Atrial natriuretic peptide (ANP) is a cardiac hormone th

129 Atrial natriuretic peptide (ANP) is a hormone involved i

130 Atrial natriuretic peptide (ANP) is a hormone with diure

131 Atrial natriuretic peptide (ANP) is a hormone with numer

132 The receptor for atrial natriuretic peptide (ANP) is a type-I transmembra

133 Atrial natriuretic peptide (ANP) is an endogenous peptid

134 We have previously shown that atrial natriuretic peptide (ANP) is present in caveolae

135 Atrial natriuretic peptide (ANP) is synthesized in the k

136 ug 44b administered at 10 mg/kg po on plasma atrial natriuretic peptide (ANP) levels in conscious rat

137 failure is characterized by elevated plasma atrial natriuretic peptide (ANP) levels, but little is k

138 nd norepinephrine (NE) increased both OP and atrial natriuretic peptide (ANP) mRNA levels twofold to

139 of this study was to examine the effects of atrial natriuretic peptide (ANP) on cytosolic Ca2+ oscil

140 the impact of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) on sodium homeostasis i

141 intravital microscopy to study the effect of atrial natriuretic peptide (ANP) on the extrasplenic mic

142 the major and possibly the only receptor for atrial natriuretic peptide (ANP) or B-type natriuretic p

143 Atrial natriuretic peptide (ANP) or B-type natriuretic p

144 Cyclic GMP (cGMP) made in response to atrial natriuretic peptide (ANP) or nitric oxide (NO) is

145 orskolin), we found that low doses of either atrial natriuretic peptide (ANP) or NO donors potentiate

146 Disruption of the atrial natriuretic peptide (ANP) receptor [guanylyl cycl

147 extracellular hormone binding domain of the atrial natriuretic peptide (ANP) receptor contains two p

148 The atrial natriuretic peptide (ANP) receptor is a 130-kDa t

149 The most studied member is the atrial natriuretic peptide (ANP) receptor, which is invo

150 y and guanylyl cyclase catalytic) domains of atrial natriuretic peptide (ANP) receptor-A (Npra) in po

151 Plasma volume fell, and plasma atrial natriuretic peptide (ANP) rose, after LPS adminis

152 st that oxytocin may mediate stretch-induced atrial natriuretic peptide (ANP) secretion.

153 ism for antiapoptotic signaling initiated by atrial natriuretic peptide (ANP) stimulation leading to

154 ier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular pe

155 Atrial natriuretic peptide (ANP) via its guanylyl cyclas

156 Circulating chimeric atrial natriuretic peptide (ANP) was detected in high co

157 ive partition analysis indicated that (125)I-atrial natriuretic peptide (ANP) was rapidly released in

158 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently geneticall

159 ition, plasma arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) were determined at the

160 enzyme) is a cardiac protease that activates atrial natriuretic peptide (ANP), a cardiac hormone that

161 nd treat systemic hypertension by expressing atrial natriuretic peptide (ANP), a hormone able to decr

162 However, atrial natriuretic peptide (ANP), a proposed ligand for

163 RP17 in cardiomyocytes enhances secretion of atrial natriuretic peptide (ANP), a regulator of blood p

164 al structures of the complexes of NPR-C with atrial natriuretic peptide (ANP), and with brain natriur

165 Concentrations of atrial natriuretic peptide (ANP), brain natriuretic pept

166 Atrial natriuretic peptide (ANP), C-type natriuretic pep

167 translated region of NPPA, the gene encoding atrial natriuretic peptide (ANP), is associated with blo

168 blood pressure and fluid homeostasis by the atrial natriuretic peptide (ANP), making PDE2-type enzym

169 nous neuropeptides, endothelin-3 (ET-3), and atrial natriuretic peptide (ANP), modulate the prolifera

170 The receptor for atrial natriuretic peptide (ANP), natriuretic peptide re

171 f the endogenous anti-proliferative peptide, atrial natriuretic peptide (ANP), on the ability of MAPK

172 A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in

173 Atrial natriuretic peptide (ANP), relaxin, glucagon, pro

174 pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin

175 ases in vascular permeability in response to atrial natriuretic peptide (ANP), which acts with the ki

176 GC) activity of the receptor protein in both atrial natriuretic peptide (ANP)-dependent and -independ

177 Nitric oxide (NO)- and atrial natriuretic peptide (ANP)-initiated cGMP signalin

178 exin A6 (Anxa6) to be a crucial regulator of atrial natriuretic peptide (ANP)-mediated counterhypertr

179 component of the intracellular modulation of atrial natriuretic peptide (ANP)-stimulated activation o

180 an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

181 production of vasodilatory peptides, such as atrial natriuretic peptide (ANP).

182 uanylate cyclase that acts as a receptor for atrial natriuretic peptide (ANP).

183 ene expression and production and release of atrial natriuretic peptide (ANP).

184 ular leak can be prevented by treatment with atrial natriuretic peptide (ANP).

185 y and degrades natriuretic peptides, such as atrial natriuretic peptide (ANP).

186 p between ADH secretion and the secretion of atrial natriuretic peptide (ANP).

187 enous neuropeptides, endothelin-3 (ET-3) and atrial natriuretic peptide (ANP).

188 tor A (NPR-A) is the biological receptor for atrial natriuretic peptide (ANP).

189 ATA4) that encodes a transcription factor of atrial natriuretic peptide (ANP).

190 onse both to volume expansion and to infused atrial natriuretic peptide (ANP).

191 blunted natriuretic and diuretic response to atrial natriuretic peptide (ANP).

192 ct mRNA and to detect expression of iNOS and atrial natriuretic peptide (ANP).

193 udy tested the hypothesis that activation of atrial natriuretic peptide (ANP)/cGMP/protein kinase G s

194 lamines, renin, aldosterone, angiotensin and atrial natriuretic peptides (ANP, N-ANP and BNP) were me

195 Moreover, while levels of mRNA encoding atrial natriuretic peptide are reduced in E17.5 GR(-/-)

196 contribute) is the key process through which atrial natriuretic peptide attenuates elevations in cyto

197 ales, cardiac expression of the precursor of atrial natriuretic peptide B and of adrenomedullin also

198 neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.

199 assessed the relations of plasma N-terminal atrial natriuretic peptide, B-type natriuretic peptide,

200 l, carbonyls), hypertrophic gene expression (atrial natriuretic peptide, B-type natriuretic peptide,

201 tricular expressions of the genes coding for atrial natriuretic peptide, beta myosin heavy chain, med

202 levels by more than 50% within 3 h and 125I-atrial natriuretic peptide binding by approximately 50%

203 a lesser extent, VD3 effected a reduction in atrial natriuretic peptide, brain natriuretic peptide, a

204 g expression of the hypertrophy gene markers atrial natriuretic peptide, brain natriuretic peptide, b

205 The reduction of atrial natriuretic peptide cannot be responsible for the

206 Synthetic atrial natriuretic peptide (carperitide) and B-type natr

207 or-stimulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardi

208 The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase.

209 Corin (also known as atrial natriuretic peptide-converting enzyme) is a cardi

210 This report implicates perturbation of the atrial natriuretic peptide-cyclic guanosine monophosphat

211 g both the renin-angiotensin-aldosterone and atrial natriuretic peptide-degrading systems simultaneou

212 f rats with RO-25-6760 for 7 d increased the atrial natriuretic peptide-dependent excretion of sodium

213 Atrial natriuretic peptide-dependent guanylate cyclase a

214 The concentrations of atrial natriuretic peptide did not differ significantly

215 We show that atrial natriuretic peptide does not modulate the release

216 ressed in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by sp

217 the addition of cGMP intracellularly, or of atrial natriuretic peptide extracellularly, stimulated i

218 guanylyl cyclase-A (GC-A), the receptor for atrial natriuretic peptide, five are conserved within GC

219 Phase 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the

220 iogenesis, increased Akt activity, decreased atrial natriuretic peptide gene expression, and maintena

221 ed with the negative regulation of the human atrial natriuretic peptide gene promoter by these mutant

222 ntricular myocytes, with increased secretory atrial natriuretic peptide granules and degenerative mye

223 ed the effect of Ras overexpression on human atrial natriuretic peptide (hANP) gene expression, a mar

224 ns, the most intriguing have been the use of atrial natriuretic peptide in patients with nonoliguric

225 angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the exercise and control g

226 angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the training and control g

227 mm(2), P < 0.01) and marker gene expression (atrial natriuretic peptide increased by 409 +/- 32%, and

228 Finally, we revealed that atrial natriuretic peptide increased phosphorylation of

229 rprisingly, L-CPT1 hearts contained elevated atrial natriuretic peptide, indicating induction of hype

230 lls, both the NO donor S-nitrosocysteine and atrial natriuretic peptide induced SSG1 phosphorylation,

231 Atrial natriuretic peptide is a circulating hormone that

232 Midregional pro-atrial natriuretic peptide is a newly described stable f

233 Midregional pro-atrial natriuretic peptide is a powerful predictor of ad

234 rdiomyocytes expression of the stress-marker atrial natriuretic peptide is suppressed by EMD 57033.

235 An increase in the PR interval and atrial natriuretic peptide level, consistent with adenos

236 he placebo group, P=.001) and reduced plasma atrial natriuretic peptide levels (-2.9 versus 26.9 pg/m

237 The reductions in vasopressin and atrial natriuretic peptide levels after captopril did no

238 potential therapeutic applications of mutant atrial natriuretic peptide (mANP).

239 Midregional pro-atrial natriuretic peptide may represent a clinically us

240 odilatin, the renally synthesized isoform of atrial natriuretic peptide, may improve pulmonary conges

241 ulate the reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertroph

242 The increased atrial natriuretic peptide most likely results in extrac

243 s the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis

244 enomedullin (MR-proADM), and midregional pro-atrial natriuretic peptide (MR-proANP) in a large prospe

245 sess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients after

246 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-

247 1-receptor mRNA and protein, upregulation of atrial natriuretic peptide mRNA expression, and increase

248 of diastolic function, nor the induction in atrial natriuretic peptide mRNA in the hypertrophic vent

249 ells expressed middle neurofilament (but not atrial natriuretic peptide) mRNA and protein.

250 gical domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic p

251 action of numerous other regulators such as atrial natriuretic peptide, neurotensin, and orexin B ar

252 n effect further enhanced in the presence of atrial natriuretic peptide, NO, and treprostinil.

253 n AMI is the increased cardiac expression of atrial natriuretic peptide (NP) and B-type NP, with thei

254 gated the effectiveness of plasma N-terminal atrial natriuretic peptide (NT-ANP) and brain natriureti

255 of this study was to examine the effects of atrial natriuretic peptide on potentially harmful elevat

256 th increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment

257 in men, P<0.001 in women) and N-terminal pro-atrial natriuretic peptide (P<0.001 in men, P=0.001 in w

258 ase in cyclic GMP in response to 1 microM of atrial natriuretic peptide, p < .05).

259 one (NT-pro-BNP), and N-terminal fragment of atrial natriuretic peptide pro-hormone (NT-pro-ANP) leve

260 93 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuret

261 In cell-based studies, corin converted pro-atrial natriuretic peptide (pro-ANP) to mature ANP, sugg

262 e hypertension, and corin activation and pro-atrial natriuretic peptide processing activity were unde

263 ented corin activation and inhibited its pro-atrial natriuretic peptide processing activity.

264 hese pathways, related to the stimulation of atrial natriuretic peptide production and secretion.

265 iously undiscovered, mechanism through which atrial natriuretic peptide protects rat hepatocytes, and

266 two categorically different models (lack of atrial natriuretic peptide receptor A; overexpression of

267 tetratricopeptide repeat (TPR) domain to the atrial natriuretic peptide receptor.

268 The atrial natriuretic peptide secreted by atrial myocytes i

269 sues and [3H]phenylalanine incorporation and atrial natriuretic peptide secretion as markers of hyper

270 termined by indices of protein synthesis and atrial natriuretic peptide secretion.

271 , V12rac1 expression leads to an increase in atrial natriuretic peptide secretion.

272 gregate (amylin, ACTH, LHRH, angiotensin II, atrial natriuretic peptide, somatostatin, oxytocin, neur

273 PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the restin

274 3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone bind

275 We show that atrial natriuretic peptide, through protein kinase G, at

276 It converts pro-atrial natriuretic peptide to atrial natriuretic peptide

277 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any

278 e was 24% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 16% lower (P<0.001); in w

279 e was 29% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 18% lower (P<0.001).

280 Atrial natriuretic peptide was 359 +/- 380 pg/mL at base

281 Atrial natriuretic peptide was found to be up-regulated

282 ncluded vasoactive peptides; the vasodilator atrial natriuretic peptide was induced by CSD, while the

283 - or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young ve

284 f response to C-type natriuretic peptide and atrial natriuretic peptide was the same as in the intact

285 gic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantita

286 s, extracellular matrix (ECM), integrin, and atrial natriuretic peptide were assessed.

287 the approximately 180-kDa fragment activated atrial natriuretic peptide, whereas the approximately 16

288 NO donors on COX-2-mRNA expression; and (c) atrial natriuretic peptide, which increases cellular cGM

289 However, the atrial natriuretic peptide, which is induced during left

290 mplants to produce sufficient amounts of the atrial natriuretic peptide, which reduced the blood pres

291 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide with metabolic risk factors,

292 estry, and identified associations of plasma atrial natriuretic peptide with rs5068 (P = 8 x 10(-70))